Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Revuelta

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
The Journal of Biological Chemistry|January 22, 2013
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeastÁlvaro Cuesta-Marbán, Javier Botet, Ola Czyz, et al.
The Journal of Veterinary Medical Science|September 15, 2017
Chemical immobilization of free-ranging and captive Sunda clouded leopards (Neofelis diardi) with two anesthetic protocols: medetomidine-ketamine and tiletamine-zolazepamFernando Nájera, Andrew J Hearn, Joanna Ross, et al.
Plos One|April 7, 2026
Evaluation of medetomidine-tiletamine-zolazepam as a partially reversible field anesthesia combination for mesocarnivoresFernando Nájera, Jamie L Palmer, Stella F Uiterwaal, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agentsVicente Escudero-Vilaplana, Roberto Collado-Borrell, Patricia Gómez Martínez-Sagrera, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 19, 2026
Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testingCarolina Pizarro-Gómez, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, et al.
Frontiers in Oncology|September 11, 2023
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapyElena Ramos-Ruperez, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, et al.
Journal of Chemotherapy (Florence, Italy)|March 10, 2026
Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitalsHéctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2021
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practiceVicente Escudero-Vilaplana, Roberto Collado-Borrell, Maria Del Monte-Millán, et al.
Journal of Personalized Medicine|August 27, 2021
<i>DPYD</i> Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype ApproachPriscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso, et al.
Frontiers in Oncology|August 8, 2022
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile AppVicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Biological Chemistry|January 22, 2013
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeastÁlvaro Cuesta-Marbán, Javier Botet, Ola Czyz, et al.
The Journal of Veterinary Medical Science|September 15, 2017
Chemical immobilization of free-ranging and captive Sunda clouded leopards (Neofelis diardi) with two anesthetic protocols: medetomidine-ketamine and tiletamine-zolazepamFernando Nájera, Andrew J Hearn, Joanna Ross, et al.
Plos One|April 7, 2026
Evaluation of medetomidine-tiletamine-zolazepam as a partially reversible field anesthesia combination for mesocarnivoresFernando Nájera, Jamie L Palmer, Stella F Uiterwaal, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agentsVicente Escudero-Vilaplana, Roberto Collado-Borrell, Patricia Gómez Martínez-Sagrera, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 19, 2026
Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testingCarolina Pizarro-Gómez, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, et al.
Frontiers in Oncology|September 11, 2023
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapyElena Ramos-Ruperez, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, et al.
Journal of Chemotherapy (Florence, Italy)|March 10, 2026
Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitalsHéctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2021
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practiceVicente Escudero-Vilaplana, Roberto Collado-Borrell, Maria Del Monte-Millán, et al.
Journal of Personalized Medicine|August 27, 2021
<i>DPYD</i> Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype ApproachPriscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso, et al.
Frontiers in Oncology|August 8, 2022
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile AppVicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, et al.
Pageof 8